Search

Now showing items 1-2 of 2

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.

Aga, E; Badal-Faesen, S; Bartlett, John A; Crump, John Andrew; Hosseinipour, MC; Katzenstein, DA; Klingman, KL; ... (13 authors) (Clin Infect Dis, 2015-05-15)

BACKGROUND: The AIDS Clinical Trials Group (ACTG) A5230 study evaluated lopinavir/ritonavir (LPV/r) monotherapy following virologic failure (VF) on first-line human immunodeficiency virus (HIV) regimens in Africa and Asia. ...

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.

Aga, E; Badal-Faesen, S; Bartlett, John A; Crump, John Andrew; Hosseinipour, MC; Kallungal, BA; Katzenstein, DA; ... (14 authors) (AIDS, 2012-07-17)

OBJECTIVE: To evaluate virologic response rates of lopinavir/ritonavir (LPV/r) monotherapy as second-line antiretroviral treatment (ART) among adults in resource-limited settings (RLSs). DESIGN: An open-label pilot study ...